Company profile
Codexis, Inc.
NASDAQ: CDXS · Healthcare · Biotechnology
#389 of 1,417 Healthcare companies by revenue64th-percentile growth
EA Score
61CFH 52DQ 78GM 50SS 68
v0.1 · 65/100 weight · provisional
↑ disclosure history, filing timeliness · ↓ 3-yr revenue growth, return on equity
Methodology →Revenue TTM
$78.1M
Rev growth YoY (TTM)
+56.8%
Net income (FY)
-$44.0M
Employees
146
as of 2026-08-13
Market cap
$172.1M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$70.4M$70.4M2025
Net income-$44.0M-$44.0M2025
Operating income-$41.7M-$41.7M2025
Total assets$147.8M$147.8M2025
Liabilities$97.3M$97.3M2025
Equity$50.5M$50.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Research And Development Revenue63%
Product37%
By geography
Americas32%
UNITED STATES32%
Asia Pacific13%
CHINA7%
EMEA7%
INDIA4%
The read
What is Codexis, Inc.’s revenue?
Codexis, Inc. booked $70.4M in FY2025 revenue, growing 19% year over year — faster than most Healthcare companies we track, at a -62.5% net margin.
Peers · Healthcare
Cue Health Inc.——Avita Medical Inc.50DViridian Therapeutics, Inc.66BBlack Diamond Therapeutics, Inc.60CPersonalis, Inc.59CRockwell Medical, Inc.60CNeighbors
San Mateo →Key facts
CEOAlison Moore
SectorHealthcare
IndustryBiotechnology
HeadquartersRedwood City, CA
ExchangeNASDAQ: CDXS
Employees146
IPO date2010-04-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.